Search

Jun 26, 2024
Spinal Cord Injury Investor Symposium: NervGen's CEO on how NVG-291 aims to block an inhibitor that may be preventing natural nervous system repair
Mike Kelly explains the scientific rational for this peptide-based treatment, highlights its preclinical and phase 1 profile, and...